Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease

• Published in: Hepatology research 2021-06, Vol.51 (6), p.641-651
• Main Authors: Song, Tiantian, Chen, Shuchun, Zhao, Hang, Wang, Fei, Song, Huan, Tian, Dongliang, Yang, Qiwen, Qi, Licui
• Format: Article
• Language: English
• Subjects: Alanine; Alanine transaminase; Aspartate aminotransferase; Collagen (type I); Diabetes; Diabetes mellitus (non-insulin dependent); Enzymes; Fatty liver; Ferritin; Fibrosis; Liver diseases; liver enzymes; liver fat; liver fibrosis; Magnetic resonance imaging; Meta-analysis; Na+/glucose cotransporter; non‐alcoholic fatty liver disease; sodium–glucose cotransporter 2; Spleen; type 2 diabetes mellitus
• ISSN: 1386-6346; 1872-034X
• DOI: 10.1111/hepr.13645

Aim This study aimed to analyze the effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors on the indexes of liver fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease, and also to observe the effects on liver enzymes and liver fat. Methods This meta‐analysis was performed using RevMan 5.3 statistical software. Results SGLT2 inhibitors could significantly reduce the level of hepatic fibrosis index: fibrosis‐4 (mean difference [MD] 0.25, 95% CI −0.39 to −0.11, p = 0.0007); serum type Ⅳ collagen 7s (MD 0.32, 95% CI −0.59 to −0.04, p = 0.02); and ferritin (MD 26.7, 95% CI 50.64, 2.76, p = 0.03). SGLT2 inhibitors could significantly reduce the level of liver enzymes: alanine aminotransferase (MD 3.49, 95% CI −5.1 to 1.58, p